Catalent - Navigating Early Drug Development Journey: Strategies for Successful Phase 1 Supported by Bionow

Catalent - Navigating Early Drug Development Journey: Strategies for Successful Phase 1 Supported by Bionow

Published on 23/02/2024
Catalent - Navigating Early Drug Development Journey: Strategies for Successful Phase 1 Supported by Bionow

Join Catalent and Bionow in Nottingham on 18th April to explore the latest strategies in bioavailability enhancement, clinical trial planning, and manufacturing for clinical success.

Small and mid-size pharmaceutical companies that have early drug development assets face unique challenges in bringing new drugs to the market. These challenges include overcoming formulation issues related to poorly soluble and permeable drugs, streamlining manufacturing processes for clinical trials, and expediting progression through clinical trials to achieve milestones critical for continued funding and investment.

This event aims to provide attendees with access to the latest advances in formulation techniques, clinical trial planning and manufacturing, as well as insights into clinical development strategy, which are pivotal in achieving successful market entry. By attending the event, participants will learn how to formulate poorly soluble and poorly permeable drugs safely and effectively, streamline manufacturing processes to reduce costs, implement efficient clinical trials, and develop early commercial plans that maximize the chances of market success. Additionally, attendees will have the opportunity to tour the Catalent Nottingham facility, where they will see firsthand how Catalent can help them translate formulation advances into clinical success.

Are you looking for a solution for your drug development challenges?

Catalent have limited slots available for a complimentary consultation with their seasoned speakers after the tour. Do not miss out on this opportunity to gain valuable insights, secure your free spot today.

REGISTER FOR FREE HERE!

Our Valued Sponsors & Partners